{'fraction_non_alphanumeric': 0.040368582711715666, 'fraction_numerical': 0.016673979815708645, 'mean_word_length': 5.263736263736264, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of a modern stroke unit combined with recombinant human tissue-type plasminogen activator intravenous thrombolysis on ischemic cerebral infarction and its influence on limb motor function and activity of daily living.

OBJECTIVE
To observe the effect of a modern stroke unit combined with recombinant human tissue-type plasminogen activator (rt-PA) intravenous thrombolysis on ischemic cerebral infarction and its impact on limb motor function and activity of daily living.


METHODS
In this prospective study, 82 patients with ischemic cerebral infarction who received treatment in our hospital were divided into two groups (41 cases in each group) according to the principle of randomized control. In the control group, patients received rt-PA intravenous thrombolysis. In the study group, patients received the modern stroke unit care combined with rt-PA intravenous thrombolysis. Before and after treatment, the clinical treatment efficacy, changes of serum inflammatory cytokines (hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6)), nerve factors (NSE, S100β), nerve function (neurologic impairment score (NIHSS)), limb motor function (Fugl-Meyer scale score (FMA)) and activity of daily living (Barthel Index score) and adverse reactions were compared between the two groups.


RESULTS
The total effective rate in the study group (92.68%) was higher than that in the control group (73.17%, P<0.01). Compared with those before treatment, the scores of NIHSS, FMA and Barthel indexes, and the levels of serum hs-CRP, IL-6, NSE and S100β were improved in both groups after treatment, and the improvement in the study group was better than that in the control group (all P<0.001). There was no statistically significant difference in the incidence of adverse reactions between the two groups (9.76% vs. 12.20%, P>0.05).


CONCLUSION
A modern stroke unit combined with rt-PA intravenous thrombolysis can effectively improve the clinical treatment efficacy, ameliorate the neurological function and limb motor function, reduce inflammatory reactions, promote the recovery of neurological function, and enhance the activity of daily living in the treatment of patients with ischemic cerebral infarction. Therefore, it is safe and worthy of further promotion.